- Home
- SPCE vs XFOR Comparison
SPCE vs XFOR Comparison
Compare SPCE & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPCE | XFOR |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.6M | 377.3M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SPCE | XFOR |
|---|---|---|
| Price | $3.01 | $2.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $3.56 | ★ $11.60 |
| AVG Volume (30 Days) | ★ 4.7M | 1.3M |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,544,000.00 | ★ $6,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23,395.24 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 150.00 |
| 52 Week Low | $2.13 | $2.80 |
| 52 Week High | $8.90 | $4.83 |
Technical Indicators
Market Signals| Indicator | SPCE | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 27.99 |
| Support Level | $2.83 | $2.83 |
| Resistance Level | $3.34 | $4.45 |
| Average True Range (ATR) | 0.17 | 0.19 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 25.25 | 18.48 |
Price Performance
Historical ComparisonAbout SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.